Histogenics (HSGX) Lowered to Strong Sell at ValuEngine
ValuEngine lowered shares of Histogenics (NASDAQ:HSGX) from a sell rating to a strong sell rating in a report released on Thursday morning.
Several other brokerages have also recently issued reports on HSGX. Zacks Investment Research raised Histogenics from a sell rating to a hold rating in a report on Wednesday, February 28th. HC Wainwright reissued a buy rating and issued a $3.50 price objective on shares of Histogenics in a report on Thursday, November 2nd. Finally, Canaccord Genuity reissued a buy rating and issued a $4.00 price objective on shares of Histogenics in a report on Thursday, December 21st.
Histogenics (NASDAQ HSGX) opened at $2.67 on Thursday. Histogenics has a fifty-two week low of $1.55 and a fifty-two week high of $3.13.
TRADEMARK VIOLATION NOTICE: “Histogenics (HSGX) Lowered to Strong Sell at ValuEngine” was first reported by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this news story can be viewed at https://www.watchlistnews.com/histogenics-hsgx-lowered-to-strong-sell-at-valuengine/1909021.html.
Histogenics Company Profile
Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company’s product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Histogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics and related companies with MarketBeat.com's FREE daily email newsletter.